Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

R. N. Davidson, L. Di Martino, L. Gradoni, R. Giacchino, G. B. Gaeta, R. Pempinello, S. Scotti, A. Cascio, E. Castagnola, A. Maisto, M. Gramiccia, D. Di Caprio, R. J. Wilkinson, A. D M Bryceson

Research output: Contribution to journalArticle

Abstract

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12 mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommend a total dose of AmBisome of ≤ 20 mg/kg, given in ≤ 5 doses of 3-4 mg/kg over ≤ 10 days.

Original languageEnglish
Pages (from-to)938-943
Number of pages6
JournalClinical Infectious Diseases
Volume22
Issue number6
Publication statusPublished - 1996

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)'. Together they form a unique fingerprint.

  • Cite this

    Davidson, R. N., Di Martino, L., Gradoni, L., Giacchino, R., Gaeta, G. B., Pempinello, R., Scotti, S., Cascio, A., Castagnola, E., Maisto, A., Gramiccia, M., Di Caprio, D., Wilkinson, R. J., & Bryceson, A. D. M. (1996). Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clinical Infectious Diseases, 22(6), 938-943.